|
|
|
|
Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis
lipid profile;liipoprotein concentrations sponsor Home-General Topics in Pediatric Email: Password: Remember me Most Viewed Abstracts 1.Top Ten Searches Your Article Summary (Click the title below to leave the MDLinx Network and go to the...
|
|
|
Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review
Today in Bone Metabolism...Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review.
|
|
|
Natural Aromatase Inhibitors are Best Prevention of Breast Cancer in Postmenopausal Women
Key concepts: Cancer, Breast cancer and Food to a friend Printable Version FREE Email Newsletter Articles Related to This Article: The mineral selenium proves itself as powerful anti-cancer medicine Cancer is not a Disease - It's a Survival...
|
|
|
NAMS Position Statement on Estrogen and Progestogen in Postmenopausal Women
_ NAMS Position Statement on Estrogen and Progestogen in Postmenopausal Women.
|
|
|
PRESS RELEASE Novartis Once-Yearly Aclasta -2- (DJ)
and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicenter, double-blind, double-dummy, randomized controlled trial.Lancet 2009; 373: 1253-63. [3.] Actonel 5mg Film Coated Tablets SPV...
|
|
|
Novartis Says Aclasta Approved In European Union To Treat Men And Postmenopausal Women With Osteoporosis - Qui
AM ET RELATED NEWS Novartis Gains FDA Nod For CAPS Orphan Drug; Trials On For Additional Indications - - Quick Facts TOP MARKET NEWS (RTTNews) - Novartis AG (NVS: News ) announced that Once-yearly Aclasta (zoledronic acid 5 mg) has been...
|
|
|
Once-Yearly Aclasta Approved in EU to Treat Osteoporosis Caused By Steroid Treatment in Men and Postmenopausal
Steroids, widely used to treat inflammatory conditions, can cause bone loss and increase risk of fractures in up to 50% of patients on long-term therapy[1] European approval based on data showing Aclasta better at increasing bone mass than...
|
|
|
Once-Yearly Aclasta Approved in EU to Treat Osteoporosis Caused By Steroid Treatment in Men and Postmenopausal
Steroids, widely used to treat inflammatory conditions, can cause bone loss and increase risk of fractures in up to 50% of patients on long-term therapy[1] European approval based on data showing Aclasta better at increasing bone mass than...
|
|
|
Obesity May Reduce Brain Gray Matter in Postmenopausal Women
Newswise Results from a small study of postmenopausal women suggest that obesity might relate to a reduced volume of gray matter in the brain.However, whether the results have relevance in a womans day-to-day life is unclear. A subset...
|
|
|
Obesity May Reduce Brain Gray Matter In Postmenopausal Women
Results from a small study of postmenopausal women suggest that obesity might relate to a reduced volume of gray matter in the brain.However, whether the results have relevance in a woman's day-to-day life is unclear. 'A subset of women...
|
|
|
Postmenopausal Hormone Treatment
_ Postmenopausal Hormone Treatment.
Journal of the American Medical Association:
Jun 16 2009 10:41PM
Matching: postmenopausal
|
Find similar documents
|
|
|
|
Effect of Multivitamins on Cancer and CVD in Postmenopausal Women
_ Effect of Multivitamins on Cancer and CVD in Postmenopausal Women.
|
|
|
Hormone therapy plus physical activity reduce belly fat, body fat percentage after menopause
Older women who take hormone therapy to relieve menopausal symptoms may get the added benefit of reduced body fat if they are physically active, according to a new study.The study provides new information on the health benefits of any...
|
|
|
After Menopause, Hormone Therapy Plus Physical Activity Reduce Belly Fat, Body Fat Percentage
Older women who take hormone therapy to relieve menopausal symptoms may get the added benefit of reduced body fat if they are physically active, according to a new study.The results were presented at The Endocrine Society's 91st Annual...
|
|
|
Hormone therapy plus physical activity reduce belly fat, body fat percentage after menopause
Older women who take hormone therapy to relieve menopausal symptoms may get the added benefit of reduced body fat if they are physically active, according to a new study.The results were presented at 's 91st Annual Meeting in Washington,...
|
|
|
HRT Break May Not Improve Mammograms
WEDNESDAY, June 3 (HealthDay News) Taking a break from hormone therapy before a mammogram doesnt lower the likelihood of being called back for extra imaging, a study including more than 1,700 women aged 45 to 80 has found....
|
|
|
Zoledronic Acid Injection Approved to Prevent Postmenopausal Osteoporosis
_ Zoledronic Acid Injection Approved to Prevent Postmenopausal Osteoporosis.
Abstracts in Hematology and Oncology:
Jun 4 2009 6:17PM
Matching: osteoporosis postmenopausal
|
Find similar documents
|
|
|
|
Zoledronic Acid Injection Approved to Prevent Postmenopausal Osteoporosis
_ Zoledronic Acid Injection Approved to Prevent Postmenopausal Osteoporosis.
|
|
|
Zoledronic Acid Injection Approved to Prevent Postmenopausal Osteoporosis
_ Zoledronic Acid Injection Approved to Prevent Postmenopausal Osteoporosis.
|
|
|
FDA Approves Reclast(R) To Prevent Osteoporosis In Postmenopausal Women With Convenient Less Frequent Dosing
Bones / Orthopaedics News Main Category: Bones / Orthopaedics Also Included In: Regulatory Affairs / Drug Approvals email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public: Health...
|
|
|
Prevalence and Impact of Vaginal Symptoms among Postmenopausal Women
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 3.Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. Prevalence and...
|
|
|
Arzoxifene May Increase Bone Mineral Density in Postmenopausal Women
_ Arzoxifene May Increase Bone Mineral Density in Postmenopausal Women.
|
|
|
FDA Approves Zoledronic Acid - Reclast(R) - to Prevent Osteoporosis in Postmenopausal Women With Convenient Le
Novartis press release - Single infusion of Reclast increases bone mass for two years in postmenopausal women with osteopenia, a condition that can lead to osteoporosis(1) - Approximately 22 million women in US have osteopenia, or low bone...
National AIDS Treatment Advocacy Project:
Jun 2 2009 9:40PM
Matching: osteoporosis postmenopausal
|
Find similar documents
|
|
|
|
Arzoxifene May Increase Bone Mineral Density in Postmenopausal Women
_ Arzoxifene May Increase Bone Mineral Density in Postmenopausal Women.
|
|
|
Arzoxifene May Increase Bone Mineral Density in Postmenopausal Women
_ Arzoxifene May Increase Bone Mineral Density in Postmenopausal Women.
|
